21.56

0.68% -0.15

Ultragenyx Pharmaceutical Inc (RARE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RARE? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$21.71

Offen:

$21.94

24-Stunden-Volumen:

745.99K

Relative Volume:

0.28

Marktkapitalisierung:

$2.08B

Einnahmen:

$610.16M

Nettoeinkommen (Verlust:

$-532.93M

KGV:

-3.8997

EPS:

-5.5287

Netto-Cashflow:

$-442.30M

1W Leistung:

+1.47%

1M Leistung:

+5.08%

6M Leistung:

-28.86%

1J Leistung:

-45.06%

1-Tages-Spanne:

$21.36

$22.27

1-Wochen-Bereich:

$21.12

$23.19

52-Wochen-Spanne:

$18.41

$42.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Firmenname

Ultragenyx Pharmaceutical Inc

Sektor

Healthcare (1118)

Branche

Biotechnology (616)

Telefon

415-483-8800

Adresse

60 LEVERONI COURT, NOVATO, CA

Mitarbeiter

1,371

Twitter

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

RARE's Discussions on Twitter

Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RARE Ultragenyx Pharmaceutical Inc	21.55	2.10B	610.16M	-532.93M	-442.30M	-5.5287
VRTX Vertex Pharmaceuticals Inc	473.70	121.46B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.79	78.93B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	705.66	43.87B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	312.82	42.07B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.42	31.65B	5.36B	287.73M	924.18M	2.5229

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-10-20	Eingeleitet	Wells Fargo	Overweight
2025-07-28	Fortgesetzt	H.C. Wainwright	Buy
2025-05-28	Eingeleitet	William Blair	Outperform
2024-06-06	Hochstufung	Goldman	Neutral → Buy
2024-04-22	Eingeleitet	RBC Capital Mkts	Outperform
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2023-06-14	Fortgesetzt	Credit Suisse	Outperform
2023-06-06	Hochstufung	Evercore ISI	In-line → Outperform
2023-04-26	Eingeleitet	Cantor Fitzgerald	Overweight
2023-01-18	Fortgesetzt	Canaccord Genuity	Buy
2022-12-30	Fortgesetzt	H.C. Wainwright	Buy
2022-11-03	Hochstufung	Robert W. Baird	Neutral → Outperform
2022-10-13	Hochstufung	Guggenheim	Neutral → Buy
2022-08-01	Herabstufung	Evercore ISI	Outperform → In-line
2022-03-16	Hochstufung	Credit Suisse	Neutral → Outperform
2022-02-11	Hochstufung	JP Morgan	Neutral → Overweight
2021-09-30	Eingeleitet	H.C. Wainwright	Buy
2021-08-19	Eingeleitet	UBS	Sell
2021-07-15	Eingeleitet	Guggenheim	Neutral
2021-06-29	Hochstufung	BofA Securities	Neutral → Buy
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-05-06	Hochstufung	Citigroup	Neutral → Buy
2021-05-06	Hochstufung	Evercore ISI	In-line → Outperform
2021-04-26	Fortgesetzt	Credit Suisse	Neutral
2021-03-02	Fortgesetzt	Stifel	Buy
2021-02-12	Herabstufung	JP Morgan	Overweight → Neutral
2020-12-07	Herabstufung	Wedbush	Outperform → Neutral
2020-11-24	Fortgesetzt	Evercore ISI	In-line
2020-11-12	Herabstufung	BofA Securities	Buy → Neutral
2019-08-02	Fortgesetzt	Wedbush	Outperform
2019-03-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2019-02-22	Fortgesetzt	Raymond James	Outperform
2019-01-02	Herabstufung	Raymond James	Outperform → Mkt Perform
2018-11-08	Hochstufung	Citigroup	Sell → Neutral
2018-09-10	Eingeleitet	Morgan Stanley	Equal-Weight
2018-06-21	Herabstufung	Credit Suisse	Outperform → Neutral
2018-05-11	Hochstufung	Barclays	Equal Weight → Overweight
2018-05-10	Eingeleitet	Goldman	Neutral
2018-04-18	Hochstufung	SunTrust	Hold → Buy
2018-03-22	Fortgesetzt	Piper Jaffray	Overweight
2018-02-21	Bestätigt	Stifel	Buy
2018-01-22	Hochstufung	Evercore ISI	In-line → Outperform
2018-01-18	Eingeleitet	Credit Suisse	Outperform
2017-12-05	Bestätigt	Barclays	Equal Weight
2017-12-04	Hochstufung	Jefferies	Hold → Buy
2017-09-14	Hochstufung	Wedbush	Neutral → Outperform

Alle ansehen

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

09:31 AM

DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit – Company AnnouncementFT.com - Financial Times

09:31 AM

08:23 AM

RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study - TradingView

08:23 AM

06:52 AM

Ultragenyx reveals positive Phase III results for DTX301 AAV8 gene therapy - The Pharmaletter

06:52 AM

05:59 AM

Russell Investments Group Ltd. Increases Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

05:59 AM

Mar 12, 2026

Bank of America, Leerink Maintain Buy/Outperform on RARE Ultragenyx March 2026 - Meyka

Mar 12, 2026

JP Morgan Lowers Price Target for Ultragenyx Pharmaceutical (RAR - GuruFocus

Mar 12, 2026

ROSEN, A LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure ... - Bluefield Daily Telegraph

Mar 12, 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $74.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Mar 12, 2026

Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder - Benzinga

Mar 12, 2026

Ultragenyx Pharmaceutical Inc Announces Positive 36-Week Data From Phase 3 Study Of DTX301 AAV8 Gene Therapy For The Treatment Of Ornithine Transcarbamylase Deficiency - marketscreener.com

Mar 12, 2026

BofA reiterates Ultragenyx stock rating on positive gene therapy data - Investing.com

Mar 12, 2026

Leerink Partners reiterates Ultragenyx stock rating on trial data - Investing.com India

Mar 12, 2026

Ultragenyx gene therapy posts Phase III win for urea cycle disorder - FirstWord Pharma

Mar 12, 2026

Ultragenyx posts trial win for gene therapy (RARE:NASDAQ) - Seeking Alpha

Mar 12, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire

Mar 12, 2026

Ultragenyx's gene therapy helps control ammonia levels in late-stage study - marketscreener.com

Mar 12, 2026

Ultragenyx Announces Positive 36-Week Data from Phase 3 - GlobeNewswire

Mar 12, 2026

RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - The Malaysian Reserve

Mar 12, 2026

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Mar 12, 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat

Mar 12, 2026

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire

Mar 12, 2026

Mar 11, 2026

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.

Mar 11, 2026

Assessing Ultragenyx Pharmaceutical (RARE) Valuation After Class Action And Failed Setrusumab Phase III Trials - simplywall.st

Mar 11, 2026

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.

Mar 11, 2026

Growth Value: What are the future prospects of Ultragenyx Pharmaceutical IncTake Profit & Reliable Entry Point Trade Alerts - baoquankhu1.vn

Mar 11, 2026

LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION - Finviz

Mar 11, 2026

LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION (2026-03-11) - Seeking Alpha

Mar 11, 2026

Sands Capital Management LLC Cuts Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Mar 11, 2026

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - ACCESS Newswire

Mar 11, 2026

Insider Sell: Karah Parschauer Sells Shares of Ultragenyx Pharma - GuruFocus

Mar 11, 2026

Mar 10, 2026

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire

Mar 10, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE - ChartMill

Mar 10, 2026

RARE Investors Have Opportunity to Lead Ultragenyx - GlobeNewswire

Mar 10, 2026

Investors who lost money on Ultragenyx Pharmaceutical Inc.(RARE) should contact The Gross Law Firm about pending Class ActionRARE - PR Newswire

Mar 10, 2026

Ultragenyx EVP Pinion sells $228k in shares By Investing.com - Investing.com Nigeria

Mar 10, 2026

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 10, 2026

Mar 09, 2026

Biopharma Brass Hid Drug Trial Risks, Derivative Suit Says - Law360

Mar 09, 2026

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - Financial Times

Mar 09, 2026

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ultragenyx - GlobeNewswire

Mar 09, 2026

Levi & Korsinsky, LLP: Institutional Investor Notice --- Ultragenyx Pharmaceutical Lead Plaintiff Opportunity - GlobeNewswire

Mar 09, 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.6%Still a Buy? - MarketBeat

Mar 09, 2026

Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire

Mar 09, 2026

FinancialContentUltragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - FinancialContent

Mar 09, 2026

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Richtech Robotics Inc. (RR), Ultragenyx Pharmaceutical Inc. (RARE), and Mereo BioPharma Group plc (MREO) Announced by Holzer & Holzer, LLC - marketscreener.com

Mar 09, 2026

Mar 08, 2026

CLASS ACTION INVESTOR ALERTS: Bragar Eagel & Squire, P.C. - GlobeNewswire

Mar 08, 2026

RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors with Losses to Contact the Firm - Financial Times

Mar 08, 2026

Mar 07, 2026